The trial is investigating IMU-838 as a treatment for hospitalized patients with moderate COVID-19 and as a potential treatment for future viral pandemic threats. The trial is being conducted under an investigational new drug application granted by the U.S. Food and Drug Administration. The company anticipates results for the phase II trial to be available in early 2021. At this point, the company will assess if the trial can be expanded into a confirmatory phase III trial.

IMU-838 inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH. It acts on activated T and B cells, leaving other immune cells largely unaffected, and allows the immune system to stay functioning.

Immunic gets funding for lead COVID-19 therapeutic candidate
Immunic has inked a 24.5 million euro ($29 million U.S.) financing agreement with the European Investment Bank.

Immunic posts interim results for COVID-19 immunotherapy trial
Immunic released positive interim results from an ongoing phase II safety and efficacy clinical trial for its dihydroorotate dehydrogenase product, IMU-838,...

Immunic begins phase II trial of COVID-19 immunotherapy
Immunic has enrolled the first patients in a phase II clinical trial of IMU-838, a selective oral dihydroorotate dehydrogenase inhibitor, in combination...

Immunic begins phase II immunotherapy for COVID-19
Immunic has enrolled the first COVID-19 patients in a phase II clinical trial of IMU-838, a selective oral dihydroorotate dehydrogenase (DHODH) inhibitor.